Cetuximab: Clinical Trials

989 trials of Cetuximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

492 completed, 138 terminated, 127 recruiting, 114 unknown. 641 Phase 2, 311 Phase 1, 120 Phase 3, 19 Not applicable, 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2641Completed 328, Terminated 91, Unknown 84, Recruiting 69, Active not recruiting 29, Withdrawn 24, Not yet recruiting 13, Suspended 2, Enrolling by invitation 1
Phase 1311Completed 138, Recruiting 55, Terminated 49, Active not recruiting 24, Unknown 22, Withdrawn 12, Not yet recruiting 9, Suspended 2
Phase 3120Completed 55, Recruiting 21, Unknown 16, Active not recruiting 11, Terminated 8, Not yet recruiting 5, Withdrawn 3, Suspended 1
Not applicable19Completed 7, Terminated 7, Not yet recruiting 2, Withdrawn 2, Unknown 1
Phase 47Terminated 2, Unknown 2, Completed 1, Not yet recruiting 1, Recruiting 1
Early Phase 16Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1

Follow Cetuximab: new trials by email Literature Review of Cetuximab trials Research Report on Cetuximab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC
Panitumumab N01, Cetuximab (EGFR inhibitor) - Colorectal Cancer Metastatic
Not yet recruitingFujian Medical University Union Hospital6102027-01-012026-11-04
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
RO7836748, Pembrolizumab, mFOLFIRINOX - Solid Tumors
Phase 1Not yet recruitingHoffmann-La Roche5402026-12-312026-10-30
A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation
BI 4015092, Cetuximab - Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1Not yet recruitingBoehringer Ingelheim2002026-12-072026-11-09
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC)
Phase 2Not yet recruitingWashington University School of Medicine222026-11-302026-10-15
A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
BMS-986548, Cetuximab - Advanced Solid Malignancies
Phase 1 / Phase 2Not yet recruitingBristol-Myers Squibb1712026-11-302026-11-16
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
Irinotecan, Oxaliplatin, GFH276 - CRC
Phase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.1502026-11-152026-11-06
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Phase 1Not yet recruitingPfizer2682026-11-092026-10-28
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
IL-12 GEMys, Cyclophosphamide, Fludarabine - Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
Phase 1RecruitingNational Cancer Institute (NCI)952026-11-042026-11-16
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC)
Phase 2Not yet recruitingSun Yat-sen University2292026-11-012026-10-16
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer
GFH375 + Cetuximab, Fruquintinib, Trifluridine and Tipiracil - Colorectal Cancer
Phase 3Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.3682026-11-012026-11-03
Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma
Cetuximab, Cemiplimab - Locally Advanced Cutaneous Squamous Cell Carcinoma
Phase 2Not yet recruitingMelanoma and Skin Cancer Trials Limited272026-10-302026-10-07
A KRAS Inhibitor in Participants With Advanced Solid Tumors
ETX-929 dose escalation, ETX-929 dose escalation in combination with cetuximab - Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 / Phase 2RecruitingEnsem Therapeutics3202026-10-222026-11-12
Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC
iparomlimab and tuvonralimab combined with cetuximab - Head and Neck Cancer
Phase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University262026-10-162026-10-20
A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Cetuximab and mFOLFIRI Regimen as First-Line Treatment for Recurrent or Metastatic Colorectal Cancer
QL1706 combined with cetuximab and mFOLFIRI - Colorectal Cancer
Not applicableNot yet recruitingThe First Affiliated Hospital with Nanjing Medical University552026-10-082026-10-14
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer
Phase 3RecruitingGenmab6002026-10-072026-11-16
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic
Phase 3Not yet recruitingCharite University, Berlin, Germany2672026-10-012026-07-29
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms
Phase 2Not yet recruitingEli Lilly and Company502026-10-012026-10-15
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC)
Phase 3RecruitingCorbus Pharmaceuticals Inc.2602026-09-292026-10-08
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer
Phase 4Not yet recruitingGruppo Oncologico del Nord-Ovest2802026-09-152026-07-24
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
HC034S, Erbitux (Cetuximab) - Cetuximab, Bioequivalence
Phase 1RecruitingHC Biopharma Inc.922026-09-122026-11-04

Showing 20 of 989. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (331)  ·  Squamous Cell Carcinoma of Head and Neck (170)  ·  Head and Neck Neoplasms (152)  ·  Carcinoma, Non-Small-Cell Lung (100)  ·  Colonic Neoplasms (94)  ·  Rectal Neoplasms (83)  ·  Neoplasm Metastasis (75)  ·  Neoplasms (60)  ·  Pancreatic Neoplasms (43)  ·  Carcinoma, Squamous Cell (40)  ·  Lung Neoplasms (36)  ·  Esophageal Neoplasms (25)  ·  Breast Neoplasms (23)  ·  Recurrence (21)  ·  Stomach Neoplasms (20)

Sponsors

Eli Lilly and Company (46)  ·  National Cancer Institute (NCI) (38)  ·  M.D. Anderson Cancer Center (31)  ·  Merck KGaA, Darmstadt, Germany (30)  ·  Memorial Sloan Kettering Cancer Center (19)  ·  Fudan University (18)  ·  Merck Sharp & Dohme LLC (16)  ·  Bristol-Myers Squibb (15)  ·  Sun Yat-sen University (15)  ·  Pfizer (14)  ·  Alliance for Clinical Trials in Oncology (11)  ·  Hoffmann-La Roche (11)  ·  Washington University School of Medicine (11)  ·  Dana-Farber Cancer Institute (10)  ·  Groupe Oncologie Radiotherapie Tete et Cou (10)

Countries

United States (505)  ·  France (140)  ·  China (137)  ·  Spain (115)  ·  Italy (104)  ·  Germany (89)  ·  Canada (76)  ·  South Korea (74)  ·  United Kingdom (73)  ·  Australia (71)  ·  Belgium (62)  ·  Netherlands (51)  ·  Japan (46)  ·  Taiwan (42)  ·  Poland (41)

Top investigators

Douglas Adkins, M.D. (7)  ·  Tanguy Seiwert (4)  ·  Ari Rosenberg, MD (3)  ·  Barbara A. Burtness, MD (3)

Results publications

PMID 25057165, PMID 16467544, PMID 19339720, PMID 19897418, PMID 23265711, PMID 27722750, PMID 28797458, PMID 30466310, PMID 30944020, PMID 31268130, PMID 33356421, PMID 33684371, PMID 36306483, PMID 36763936, PMID 36852723, PMID 36880426, PMID 38592721, PMID 40215447, PMID 41343184, PMID 10493478, PMID 10744089, PMID 11208820, PMID 11247898, PMID 12518365, PMID 12927569, PMID 14967461, PMID 15142632, PMID 15175435, PMID 1584260, PMID 15870084, PMID 15908664, PMID 16246975, PMID 16314626, PMID 16356309, PMID 16476835, PMID 16681848, PMID 16943526, PMID 17050875, PMID 17470860, PMID 17553204, PMID 17704420, PMID 17960012, PMID 17960013, PMID 18003960, PMID 18077217, PMID 18191993, PMID 18272912, PMID 18279058, PMID 18316791, PMID 18349029

NIH funding

2023 (13), 2009 (12), 2025 (10), 2014 (9), 2015 (9), U10CA032102 (9), 2008 (7), U10CA021115 (7), 2016 (6), 2017 (6), 2019 (6), U10CA180888 (6), P30CA068485 (5), 2018 (4), N01CM62201 (4)